Enspire Bio

Enspire Bio is a preclinical-stage biotechnology company focused on developing first-in-class small molecule therapies for neurodegenerative diseases, specifically Parkinson's disease. The company's lead program targets the Nuclear Receptor Related 1 protein (NURR1), a critical transcription factor for the development and survival of dopaminergic neurons. By activating NURR1, Enspire Bio aims to protect these neurons from degeneration and restore motor function, potentially offering a disease-modifying approach. Founded as a spin-out from the University of Utah, the company leverages proprietary chemical scaffolds to achieve high potency and selectivity. Enspire Bio is currently advancing its lead candidates through IND-enabling studies to address the significant unmet need in the Parkinson's patient population.